Specific tyrosine kinase inhibitors have shown remarkable clinical response in patients with tumors characterized by RTK activation, such as gefitinib and erlotinib in EGFR-mutated [4] and crizotinib in ALK- or ROS1-rearranged lung cancer [5, 6]. The gene discussed is ALK; the disease is lung cancer.